Oculis treats first patient in PIONEER-1 registrational trial of Privosegtor for optic neuritis - OCS News | RalliesOculis treats first patient in PIONEER-1 registrational trial of Privosegtor for optic neuritis
O
OCS• First patient dosed in PIONEER-1 registrational trial
- Oculis began dosing patients in PIONEER-1, a registrational trial of Privosegtor for acute-onset optic neuritis.
- No new efficacy results were presented; the trial’s primary analysis is planned at Month 3, with follow-up through Month 12.
- Privosegtor is positioned as a potential neuroprotective treatment designed to improve vision recovery in optic neuritis.
- The program builds on earlier Phase 2 findings that supported FDA Breakthrough Therapy designation, with an acute MS relapse IND targeted for Q4 2026.
